ASH 2023 – Ramón García-Sanz
Ramón García-Sanz gives insights into the assessment of residual disease in multiple myeloma and explains future clinical implications of these data. Moreover, he discusses in which ways the evaluation of minimal residual disease might improve the management of patients with Waldenström macroglobulinemia and shares his personal highlight from the ASH 2023 congress.
Here is the full ASH 2023 report.
More posts
Advancing care in Waldenström macroglobulinemia: Clinical and real-world perspectives
Recent advances have transformed the management of Waldenström macroglobulinemia (WM), particularly with the advent of targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors. These innovations have addressed longstanding challenges including resistance, intolerance, and the need for personalized approaches (enabling therapy also for those deemed unfit for chemotherapy).
Follicular lymphoma: Efficacy and safety updates
In the context of follicular lymphoma treatment, there is a clear unmet need for patients who have experienced early progression (progression within 24 months of front-line therapy, POD24), as well as those who are refractory to treatment and present with other high-risk features. At ASH 2024, promising efficacy and safety data were reported for the five molecules nemtabrutinib, zanubrutinib, BGB-16673, epcoritamab, and mosunetuzumab [1-6].
Pushing the boundaries further in the management of CLL
In patients with treatment-naïve chronic lymphocytic leukemia (CLL), the multicenter, open-label, randomized, phase III AMPLIFY trial was initiated to evaluate fixed-duration treatment with acalabrutinib plus venetoclax ± obinutuzumab compared to investigator’s choice of chemoimmunotherapy (CIT).
Editorial – ASH 2024
The 66th Annual Meeting of the American Society of Hematology (ASH), held as a hybrid event from December 7th to 10th, 2024, in San Diego, California, USA, set a new benchmark with over 7,950 abstracts accepted for presentation.